GLP-1 receptor agonists have a sustained stimulatory effect on corticosterone release after chronic treatment

Acta Neuropsychiatrica

Volumn 27, Issue 1, 2014, Pages 25-32

  Krass, Maarja ^a   Volke, Annika ^a   Rünkorg, Kertu ^a   Wegener, Gregers ^b,c   Lund, Sten ^d   Abildgaard, Anders ^b   Vasar, Eero ^a   Volke, Vallo ^a  

^a UNIVERSITY OF TARTU   (Estonia)

^b AARHUS UNIVERSITY   (Denmark)

^c NORTH WEST UNIVERSITY   (South Africa)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

corticosterone; exenatide; liraglutide; neuroendocrinology; stress

Indexed keywords

CORTICOSTERONE; EXENDIN 4; GLUCOSE; LIRAGLUTIDE; ANTIDIABETIC AGENT; GLP1R PROTEIN, MOUSE; GLP1R PROTEIN, RAT; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; GLUCOSE BLOOD LEVEL; PEPTIDE; VENOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ANXIETY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CORTICOSTERONE RELEASE; DEPRESSION; DRUG DOSE TITRATION; DRUG EFFECT; EXPERIMENTAL HYPOACTIVITY; FORCED SWIM TEST; GLUCOSE BLOOD LEVEL; IMMOBILITY; LIGHT-DARK TEST; LONG TERM CARE; MALE; MOTOR ACTIVITY; MOUSE; NONHUMAN; RAT; SINGLE DRUG DOSE; SWIMMING; WEIGHT GAIN; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL BEHAVIOR; BLOOD; DRUG EFFECTS; DRUG TOLERANCE; SECRETION (PROCESS);

ANIMALS; BEHAVIOR, ANIMAL; BLOOD GLUCOSE; CORTICOSTERONE; DRUG TOLERANCE; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MICE; PEPTIDES; RATS; RECEPTORS, GLUCAGON; VENOMS;

EID: 84922710800     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1017/neu.2014.36     Document Type: Article

References (26)

1. DRUCKER DJ, NAUCK MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705.
2. USSHER JR, DRUCKER DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012;33:187-215.
3. SALCEDO I, TWEEDIE D, LI Y, GREIG NH. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol 2012;166 :1586-1599.
4. LOCKIE SH. Glucagon-like peptide-1 receptor in the brain: role in neuroendocrine control of energy metabolism and treatment target for obesity. J Neuroendocr 2013;25:597-604.
5. MCKAY NJ, DANIELS D. Glucagon-like peptide-1 receptor agonist administration suppresses both water and saline intake in rats. J Neuroendocr 2013;25:929-938.
6. KANOSKI SE, RUPPRECHT LE, FORTIN SM, DE JONGHE BC, HAYES MR. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology 2012;62:1916-1927.
7. PUNJABI M, ARNOLD M, RÜTTIMANN E et al. Circulating glucagon-like peptide-1 (GLP-1) inhibits eating in male rats by acting in the hindbrain and without inducing avoidance. Endocrinology 2014;155 :1690-1699.
8. LABOUESSE MA, STADLBAUER U, WEBER E, ARNOLD M, LANGHANS W, PACHECO-LOPEZ G. Vagal afferents mediate early satiation and prevent flavour avoidance learning in response to intraperitoneally infused exendin-4. J Neuroendocr 2012;24:1505-1516.
9. DURING MJ, CAO L, ZUZGA DS et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003;9:1173-1179.
10. EGECIOGLU E, STEENSLAND P, FREDRIKSSON I, FELTMANN K, ENGEL JA, JERLHAG E. The glucagon-like peptide 1 analogue exendin-4 attenuates alcohol mediated behaviors in rodents. Psychoneuroendocrinology 2013;38:1259-1270.
11. ISACSON R, NIELSEN E, DANNAEUS K et al. The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur J Pharmacol 2011;650:249-255.
12. MOLLER C, SOMMER W, THORSELL A, RIMONDINI R, HEILIG M. Anxiogenic-like action of centrally administered glucagonlike peptide-1 in a punished drinking test. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:119-122.
13. PORSOLT RD, BERTIN A, JALFRE M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977;229:327-336.
14. KRASS M, RUNKORG K, VASAR E, VOLKE V. Acute administration of GLP-1 receptor agonists induces hypolocomotion but not anxiety in mice. Acta Neuropsychiatr 2012;24:296-300.
15. GIL-LOZANO M, PEREZ-TILVE D, VAREZ-CRESPO M et al. GLP-1 (7-36)-amide and exendin-4 stimulate the HPA axis in rodents and humans. Endocrinology 2010;151:2629-2640.
16. MALENDOWICZ LK, NERI G, NUSSDORFER GG, NOWAK KW, ZYTERSKA A, ZIOLKOWSKA A. Prolonged exendin-4 administration stimulates pituitary -adrenocortical axis of normal and streptozotocin-induced diabetic rats. Int J Mol Med 2003;12:593-596.
17. MACLUSKY NJ, COOK S, SCROCCHI L et al. Neuroendocrine function and response to stress in mice with complete disruption of glucagon-like peptide-1 receptor signaling. Endocrinology 2000;141 :752-762.
18. GIL-LOZANO M, ROMANI-PEREZ M, OUTEIRINO-IGLESIAS V et al. Effects of prolonged exendin-4 administration on hypothalamic-pituitary-adrenal axis activity and water balance. Am J Physiol Endocrinol Metab 2013;304: E1105-E1117.
19. OVERSTREET DH, WEGENER G. The flinders sensitive line rat model of depression - 25 years and still producing. Pharmacol Rev 2013;65:143-155.
20. CRAWLEY J, GOODWIN FK. Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 1980;13:167-170.
21. ABILDGAARD A, SOLSKOV L, VOLKE V, HARVEY BH, LUND S, WEGENER G. A high-fat diet exacerbates depressive-like behavior in the Flinders Sensitive Line (FSL) rat, a genetic model of depression. Psychoneuroendocrinology 2011;36:623-633.
22. DETKE MJ, RICKELS M, LUCKI I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacol 1995;121:66-72.
23. KRASS M, WEGENER G, VASAR E, VOLKE V. Antidepressantlike effect of agmatine is not mediated by serotonin. Behav Brain Res 2008;188:324-328.
24. KINZIG KP, D'ALESSIO DA, HERMAN JP et al. CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. J Neurosci 2003;23:6163-6170.
25. ALI S, STONE MA, PETERS JL, DAVIES MJ, KHUNTI K. The prevalence of co-morbid depression in adults with type 2 diabetes: a systematic review and meta-analysis. Diabet Med 2006;23:1165-1173.
26. JELSING J, VRANG N, HANSEN G, RAUN K, TANG-CHRISTENSEN M, KNUDSEN LB. Liraglutide: short-lived effect on gastric emptying - long lasting effects on body weight. Diabetes Obes Metab 2012;14:531-538.